Therapy Finder Advisor
Section Chief, Gastrointestinal Oncology Chair,
OSUCCC Gastrointestinal Disease Research Group,
Associate Professor of Medicine and Pharmacology,
The Ohio State University – James Cancer Hospital
|Stivarga, regorafenib||FLT1, KDR, FLT4, KIT, TEK, PDGFRB, PDGFRA, FGFR1, FGFR2, NTRK1, MAPK11, BRAF, ABL1, EPHA2, RAF1, RET, FRK||Bayer AG||FDA approved for: Colorectal Cancer, Gastrointestinal Stromal Tumor (GIST)|
Dear Therapy Finder® User:
During the past two years we have witnessed an unprecedented upswing in research activity leading to the identification of increasing numbers of actionable biomarkers and several effective targeted treatments. To accommodate this dramatic increase in the number of relevant biomarkers, their interactions, and other patient attributes, we are developing a new application design, one that will be both easier to use and more relevant to practicing physicians and patients. This new system will unify many of the best features and key learnings from the Therapy Finders with those from our Genomic Variant Annotation™ (GVA) reporting system.
Until we complete the redesign of our Therapy Finders or offer substitute decision-support products, we are suspending the updating of the Therapy Finders appearing on the CollabRx website and other sites.
If you click through and decide to use the Colon Cancer, Lung Cancer, Melanoma or Metastatic Breast Cancer Therapy Finders, please do so with caution, as some of the data have not been updated since October 15, 2014.
July 6, 2015